• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [24901 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2010     The Netherlands Organisation for Health Research and Development (ZonMw) [Computer-assisted minimally invasive total hip surgery (MIS): a randomised controlled trial into the effectiveness compared to traditional total hip arthroplasty (THA)]
2007     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Computer-assisted surgery in knee surgery - a health technology assessment]
2008     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Computer-based cognitive behavioral therapy]
2000     Basque Office for Health Technology Assessment (OSTEBA) [Computerised axial tomography: equipments and use in the ACBC. Instructions on the appropriate use of CAT]
2023     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Computerized clinical decision support systems for decision support in patients with breast, lung, colorectal or prostate cancer]
2009     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Computerized physician order entry - effectiveness and efficiency of electronic medication ordering with decision support systems]
2009     The Swedish Council on Health Technology Assessment (SBU) [Computerized training for children with ADHD]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for a national health portal]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection - autologous anti-CD19-transduced CD3+ cells]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection - epcoritamab (relapsed or refractory follicular lymphoma)]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection - iptacopan (paroxysmal nocturnal haemoglobinuria)]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection - marstacimab (haemophilia A and B)]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection – Belumosudil (chronic graft-versus-host disease)]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection – epcoritamab (DLBCL)]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection – glofitamab (DLBCL)]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection – loncastuximab (DLBCL)]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection – Odronextamab (relapsed or refractory DLBCL)]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection – Odronextamab (relapsed or refractory follicular lymphoma)]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection – Valoctocogen roxaparvovec: review of the study protocol (version 2.0) and the statistical analysis plan (version 2.0) – 3. Addendum to project A22-20]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection acc. to the Law for More Safety in the Supply of Medicines (GSAV) – exagamglogene autotemcel (beta-thalassaemia)]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection acc. to the Law for More Safety in the Supply of Medicines (GSAV) – exagamglogene autotemcel (sickle cell disease)]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection acc. to the Law for More Safety in the Supply of Medicines (GSAV): talquetamab (multiple myeloma)]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection for brexucabtagene autoleucel acc. to the Law for More Safety in the Supply of Medicines (GSAV)]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection for etranacogene dezaparvovec acc. to the Law for More Safety in the Supply of Medicines (GSAV)]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection for fedratinib acc. to the Law for More Safety in the Supply of Medicines (GSAV)]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection for risdiplam acc. to the Law for More Safety in the Supply of Medicines (GSAV)]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection for valoctocogene roxaparvovec acc. to the Law for More Safety in the Supply of Medicines (GSAV): Evaluation of the study protocol (Version 1.0) and the statistical analysis plan (Version1.0) – Second addendum to Commission A22-20]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection for valoctocogene roxaparvovec acc. to the Law for More Safety in the Supply of Medicines (GSAV)]
2009     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Concepts of care for people with dementia]
2021     Gesundheit Osterreich GmbH (GOeG) [Concepts, indicators and measurement instruments for recording the impact of anti-stigma measures in mental health - quick assessment]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concizumab (haemophilia A, haemophilia B) – Addendum to Projects A25-55 and A25-56]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concizumab (haemophilia A) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concizumab (haemophilia A) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concizumab (haemophilia B) – Addendum to Project A25-56]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concizumab (haemophilia B) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concizumab (haemophilia B) – Benefit assessment according to §35a Social Code Book V]
2008     The Netherlands Organisation for Health Research and Development (ZonMw) [Conditions for regional implementation of a national careprogramme anxiety disorders, based on the multidisciplinary evidence based guideline on anxiety disorders]
2023     Canary Health Service [Conduction system pacing implantation through electroanatomical mapping-guided vs. fluoroscopy]
2022     HTA South [Conductive education in cerebral palsy]
2022     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Conductive intravesical chemohyperthermia with mitomycin in non-muscle invasive bladder cancer: review of guidelines and ongoing research]
2009     Basque Office for Health Technology Assessment (OSTEBA) [Confidentiality of medical records. Analysis of the current situation and areas for improvement in their use and management]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Confirmed trichomonas vaginalis infection: pharmacological treatment]
2010     Andalusian Health Technology Assessment Area (AETSA) [Confocal microscopy in ophthalmology: Report summary of emergent technology]
2008     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Congenital hypothyroidism: clinical practice guideline]
2021     Health Sciences Institute in Aragon (IACS) [Congenital ventricular septal defect (VSD) treatment with percutaneous and periventricular insertion devices]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Consensus recommendations on post-traumatic brain injury (TBI) rehabilitation]
2008     Center for Medical Technology Assessment (CMT) [Consequences appearing to family carers]
2024     Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS) [Considerations related to risk treatment in the context of home care for older adults and courses of action to support care providers]
2011     Agenzia nazionale per i servizi sanitari regionali (Agenas) [Consultation on the spread of tele-assistance for the management of the patient in post-stroke rehabilitation]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Consumer health information on lung cancer screening using low-dose computed tomography]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Consumer health information on smoking cessation options]
2012     Basque Office for Health Technology Assessment (OSTEBA) [Contaminants from the treatment of drinking water in the Autonomous Community of the Basque Country: Assessment of the risk and alternative treatments]
2021     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Continuity of care]
2008     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Continuous anaesthetic infusion system at the surgical site]
2005     Andalusian Health Technology Assessment Area (AETSA) [Continuous blood glucose monitoring system "GlucoWatch"]
2009     Committee for New Health Technology Assessment (CNHTA) [Continuous femoral nerve block]
2010     The Netherlands Organisation for Health Research and Development (ZonMw) [Continuous flow registration for early detection of hepatic artery thrombosis after liver transplantation. Innovative technology reducing retransplantation rate?]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Continuous interstitial glucose monitoring (CGM) with real-time measurement devices in insulin-dependent diabetes mellitus]
2010     Committee for New Health Technology Assessment (CNHTA) [Continuous local delivery of anesthesia to operative sites using an elastomeric infusion pump]
2013     The Swedish Council on Health Technology Assessment (SBU) [Continuous subcutaneous glucose monitoring for diabetes]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Continuous subcutaneous infusion pump for diabetic patients]
2012     Finnish Office for Health Care Technology Assessment (Finohta) [Continuous subcutaneous insulin infusion in type 1 diabetes mellitus]
2011     Finnish Office for Health Care Technology Assessment (Finohta) [Continuous wound infusion of local anaesthetic agents for postoperative analgesia]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Contraception: comparison of hormonal coils and copper coils]
2019     Basque Office for Health Technology Assessment (OSTEBA) [Controlled and uncontrolled donation after circulatory death with regional normothermic or hypothermic perfusion based on extracorporeal membrane oxygenation for kidney and liver transplants]
2008     The Netherlands Organisation for Health Research and Development (ZonMw) [Conventional Or Magnetic resonance angiography after Endovascular Treatment of intracranial aneurysms (COMET)]
2021     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Coping strategies in complex medical situations - the example of coronary heart disease]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Core decompression: Evidence report for the S3 guideline on atraumatic femoral head necrosis in adults]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Corifollitropin alfa (Elonva®) for controlled ovarian stimulation in assisted human reproductive techniques]
2015     Haute Autorite de sante (HAS) [Corneal collagen cross-linking and intrastromal corneal ring segments in the treatment of corneal ectasia]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Corneal collagen crosslinking for keratoconus patients]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Corneal collagen crosslinking with riboflavin for keratoconus patients]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Corneal collagen crosslinking with riboflavin in keratoconus]
2009     Committee for New Health Technology Assessment (CNHTA) [Corneal cross linking]
2001     Finnish Office for Health Care Technology Assessment (Finohta) [Coronary angioplasty in Finland: an overview of the situation in 2000 and an estimation of needs in the near future]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Coronary intravascular lithotripsy in coronary artery disease]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Coronary lithoplasty for coronary heart disease - Addendum to commission H20-07]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Coronary lithoplasty for coronary heart disease - Assessment according to §137h Social Code Book V]
2024     Basque Office for Health Technology Assessment (OSTEBA) [Coronary sinus reducer stent for patients with refractory angina]
2013     Basque Office for Health Technology Assessment (OSTEBA) [CORREX® aortic valve bypass for treatment of severe aortic stenosis]
2008     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Corticosteroid therapy in the treatment of pediatric patients with atopic dermatitis]
2007     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Corticosteroid therapy in the treatment of pediatric patients with atopic dermatitis]
2014     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Cost and budget impact analysis of an increase in day surgery for selected indications]
2015     Basque Office for Health Technology Assessment (OSTEBA) [Cost effective analysis of negative pressure wound therapy for the treatment of venous ulcers in legs]
2011     The Netherlands Organisation for Health Research and Development (ZonMw) [Cost effectiveness of a collaborative stepped care intervention for anxiety disorders in the primary care setting]
2022     Gesundheit Osterreich GmbH (GOeG) [Cost effectiveness of communication training for health care professionals]
2014     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Cost effectiveness of different types of coronary stents which are used in patients with acute coronary syndrome (ACS)]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [Cost effectiveness of scalp cooling in the prevention of chemotherapy-induced hair loss]
2008     The Netherlands Organisation for Health Research and Development (ZonMw) [Cost effectiveness of two different implementation procedures to change clinicians practice roles in the detection of hereditary colorectal cancer]
2012     Basque Office for Health Technology Assessment (OSTEBA) [Cost evaluation of the early breast cancer detection programme of the Autonomous Community of the Basque Country]
2015     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Cost studies of type 2 diabetes: a review of literature]
2011     Health Intervention and Technology Assessment Program (HITAP) [Cost-benefit analysis of prenatal screening and diagnosis for Down syndrome in Thailand]
2010     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [Cost-benefits evaluation of prevention and control of nosocomial MRSA infections]
2023     Center for Outcomes Research and Economic Evaluation for Health (C2H) [Cost-effective analysis evaluation of galcanezumab (Emgality)]
2007     Canary Health Service [Cost-effectiveness analysis and health outcomes in orthopedic surgery of the hip and knee]
2012     Basque Office for Health Technology Assessment (OSTEBA) [Cost-effectiveness analysis of a telemonitoring experiment in patients with cardiac insufficiency and chronic obstructive pulmonary disease]
2008     Canary Health Service [Cost-effectiveness analysis of breast cancer screening by mammography in different age groups (40-49, 50-69 and 70-75)]
2010     Canary Health Service [Cost-effectiveness analysis of colorectal cancer screening in general population]
2013     Canary Health Service [Cost-effectiveness analysis of microarrays for prenatal diagnosis of genetic aberrations in Spain]
2020     Canary Health Service [Cost-effectiveness analysis of newborn screening for severe combined immunodeficiency]